TY - JOUR
T1 - Directed Evolution of Canonical Loops and Their Swapping between Unrelated Serine Proteinase Inhibitors Disprove the Interscaffolding Additivity Model
AU - Boros, Eszter
AU - Sebák, Fanni
AU - Héja, Dávid
AU - Szakács, Dávid
AU - Zboray, Katalin
AU - Schlosser, Gitta
AU - Micsonai, András
AU - Kardos, József
AU - Bodor, Andrea
AU - Pál, Gábor
N1 - Funding Information:
Fund Grants K119386 , K120391 , K124900 and KH125597 ; by the European Union and the State of Hungary and co-financed by the European Regional Development Fund within the projects VEKOP-2.3.2-16-2017-00014 and VEKOP-2.3.3-15-2017-00020 ; and by the Hungarian Ministry of Human Capacities in the frame of the ELTE Institutional Excellence Program ( 783-3/2018/FEKUTSRAT ), as well as by the MedInProt Protein Science Research Synergy Program of the Hungarian Academy of Sciences and by the National Development Agency Grant KMOP-4.2.1/B-10-2011 . A.M. was supported by the János Bolyai Scholarship of the Hungarian Academy of Sciences.
Funding Information:
This work was supported by the National Research, Development and Innovation Office/Hungarian Scientific ResearchFund Grants K119386, K120391, K124900 and KH125597; by the European Union and the State of Hungary and co-financed by the European Regional Development Fund within the projects VEKOP-2.3.2-16-2017-00014 and VEKOP-2.3.3-15-2017-00020; and by the Hungarian Ministry of Human Capacities in the frame of the ELTE Institutional Excellence Program (783-3/2018/FEKUTSRAT), as well as by the MedInProt Protein Science Research Synergy Program of the Hungarian Academy of Sciences and by the National Development Agency Grant KMOP-4.2.1/B-10-2011. A.M. was supported by the J?nos Bolyai Scholarship of the Hungarian Academy of Sciences.
Funding Information:
This work was supported by the National Research, Development and Innovation Office/Hungarian Scientific Research
Publisher Copyright:
© 2018 Elsevier Ltd
PY - 2019/2/1
Y1 - 2019/2/1
N2 - Reversible serine proteinase inhibitors comprise 18 unrelated families. Each family has a distinct representative structure but contains a surface loop that adopts the same, canonical conformation in the enzyme–inhibitor complex. The Laskowski mechanism universally applies for the action of all canonical inhibitors independent of their scaffold, but it has two nontrivial extrapolations. Intrascaffolding additivity states that all enzyme-contacting loop residues act independently of each other, while interscaffolding additivity claims that these residues act independently of the scaffold. These theories have great importance for engineering proteinase inhibitors but have not been comprehensively challenged. Therefore, we tested the interscaffolding additivity theory by hard-randomizing all enzyme-contacting canonical loop positions of a Kazal- and a Pacifastin-scaffold inhibitor, displaying the variants on M13 phage, and selecting the libraries on trypsin and chymotrypsin. Directed evolution delivered different patterns on both scaffolds against both enzymes, which contradicts interscaffolding additivity. To quantitatively assess the extent of non-additivity, we measured the affinities of the optimal binding loop variants and their binding loop-swapped versions. While optimal variants have picomolar affinities, swapping the evolved loops results in up to 200,000-fold affinity loss. To decipher the underlying causes, we characterized the stability, overall structure and dynamics of the inhibitors with differential scanning calorimetry, circular dichroism and NMR spectroscopy and molecular dynamic simulations. These studies revealed that the foreign loop destabilizes the lower-stability Pacifastin scaffold, while the higher-stability Kazal scaffold distorts the foreign loop. Our findings disprove interscaffolding additivity and show that loop and scaffold form one integrated unit that needs to be coevolved to provide high-affinity inhibition.
AB - Reversible serine proteinase inhibitors comprise 18 unrelated families. Each family has a distinct representative structure but contains a surface loop that adopts the same, canonical conformation in the enzyme–inhibitor complex. The Laskowski mechanism universally applies for the action of all canonical inhibitors independent of their scaffold, but it has two nontrivial extrapolations. Intrascaffolding additivity states that all enzyme-contacting loop residues act independently of each other, while interscaffolding additivity claims that these residues act independently of the scaffold. These theories have great importance for engineering proteinase inhibitors but have not been comprehensively challenged. Therefore, we tested the interscaffolding additivity theory by hard-randomizing all enzyme-contacting canonical loop positions of a Kazal- and a Pacifastin-scaffold inhibitor, displaying the variants on M13 phage, and selecting the libraries on trypsin and chymotrypsin. Directed evolution delivered different patterns on both scaffolds against both enzymes, which contradicts interscaffolding additivity. To quantitatively assess the extent of non-additivity, we measured the affinities of the optimal binding loop variants and their binding loop-swapped versions. While optimal variants have picomolar affinities, swapping the evolved loops results in up to 200,000-fold affinity loss. To decipher the underlying causes, we characterized the stability, overall structure and dynamics of the inhibitors with differential scanning calorimetry, circular dichroism and NMR spectroscopy and molecular dynamic simulations. These studies revealed that the foreign loop destabilizes the lower-stability Pacifastin scaffold, while the higher-stability Kazal scaffold distorts the foreign loop. Our findings disprove interscaffolding additivity and show that loop and scaffold form one integrated unit that needs to be coevolved to provide high-affinity inhibition.
KW - SPINK1
KW - directed evolution
KW - molecular recognition
KW - phage display
KW - protein–protein interaction
UR - http://www.scopus.com/inward/record.url?scp=85059853117&partnerID=8YFLogxK
U2 - 10.1016/j.jmb.2018.12.003
DO - 10.1016/j.jmb.2018.12.003
M3 - Article
C2 - 30543823
AN - SCOPUS:85059853117
SN - 0022-2836
VL - 431
SP - 557
EP - 575
JO - Journal of Molecular Biology
JF - Journal of Molecular Biology
IS - 3
ER -